Evidence map›Paper›PMID 38619655›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

Production of [

Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. First-in-Human Study of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Scale-up production of [EJNMMI radiopharmacy and chemistry · 2025
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Sadahiro NakaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Kazuhiro OoeInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yoshifumi ShirakamiInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Kenta KurimotoDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Toshihiro SakaiHanwa Intelligent Medical Center, Hanwa Daini Senboku Hospital, 3176 Fukaikitamachi, Naka- ku, Sakai, Osaka, 599-8271, Japan.
Kazuhiro TakahashiAdvanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Atsushi ToyoshimaInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yang WangNishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan.
Hiromitsu HabaNishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan.
Hiroki KatoDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Noriyuki TomiyamaInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Tadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. watabe.tadashi.med@osaka-u.ac.jp.ORCID http://orcid.org/0000-0001-8658-2395
The University of Osaka · JPOsaka University Hospital · JPRIKEN Nishina Center · JPFukushima Medical University · JP

Funding

Japan Agency for Medical Research and Development 20lk0201107h0001Japan Agency for Medical Research and Development 20lm0203109h0001Japan Agency for Medical Research and Development 22lk0201139h0002Japan Science and Technology Agency JPMJOP1721
6 · The paper itself

Abstract

backgroundThe alpha emitter astatine-211 (

results

conclusionsWe successfully established a stable method of [

Indexed as

[211At]NaAtAstatineAutomated dry distillation systemTargeted alpha therapyThyroid cancer

Identifiers

PMID38619655
PMCPMC11018728
OpenAlexW4394811008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.